![Mark Manfredi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Manfredi
Directeur Général chez
DISCO Pharmaceuticals GmbH
Fortune : 68 919 $ au 31/05/2026
Profil
Mark Manfredi was the founder of Ikena Oncology, Inc., founded in 2016, where the title held was Chief Scientific Officer from 2016 to 2017.
Current jobs include Chief Executive Officer at DISCO Pharmaceuticals GmbH starting in 2025, President at Amplify Medicines, Inc., and Advisor at Atlas Venture Advisors, Inc. Former jobs include President & Chief Executive Officer at ImageneBio, Inc., Chief Scientific Officer at Raze Therapeutics, Inc. from 2015 to 2016, and Vice President-Oncology at Takeda Pharmaceutical Co., Ltd. Education includes undergraduate studies at the University of Rhode Island and a doctorate from Boston College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,1% | 28/04/2026 | 11 721 ( 0,1% ) | 68 919 $ | 31/05/2026 |
Postes actifs de Mark Manfredi
| Sociétés | Poste | Début |
|---|---|---|
Amplify Medicines, Inc.
 Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Develops pharmaceutical drugs | President | - |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Consultant / Advisor | - |
DISCO Pharmaceuticals GmbH
 DISCO Pharmaceuticals GmbH BiotechnologyHealth Technology Develops cancer therapies | Directeur Général | 11/12/2025 |
Anciens postes connus de Mark Manfredi
| Sociétés | Poste | Fin |
|---|---|---|
Raze Therapeutics, Inc.
 Raze Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops oncology therapeutics | Directeur Technique/Scientifique/R&D | 01/04/2016 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
| IMAGENEBIO, INC. | Directeur Général | - |
Formation de Mark Manfredi
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
9
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Takeda Pharmaceutical Co., Ltd.
 Takeda Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research, development, manufacturing and marketing of pharmaceutical products | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Finance |
University of Rhode Island
 University of Rhode Island Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boston College
 Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Raze Therapeutics, Inc.
Raze Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops oncology therapeutics | Health Technology |
Ikena Oncology, Inc.
 Ikena Oncology, Inc. BiotechnologyHealth Technology Develops metabolic enzymes based immunotherapy for oncology applications | Health Technology |
Amplify Medicines, Inc.
Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Develops pharmaceutical drugs | Health Technology |
DISCO Pharmaceuticals GmbH
DISCO Pharmaceuticals GmbH BiotechnologyHealth Technology Develops cancer therapies | Health Technology |
